In fact, sabatolimab, a humanized IgG4 anti TIM3 mAb, is the only TIM3 inhibitor currently being studied in AML and MDS clinical trials in monotherapy or in combination with other drugs (e.g., venetoclax, HMAs); it has shown promising response rates and manageable toxicities [131]. This evidence concerns the gene HAVCR2 and myelodysplastic syndrome.